Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/semaglutide/florida/delray-beach
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Delray Beach, FL

Verified Semaglutide providers in Delray Beach, FL. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
32
as of today
§ 02Provider directory: Florida
32 of 32 shown

Find a Semaglutide provider in Florida.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Florida city · /semaglutide/florida/{city}
Boca Raton
26.37°N
42 →
Coral Springs
26.27°N
31 →
Wellington
26.65°N
28 →
West Palm Beach
26.75°N
41 →
Fort Lauderdale
41 →
Plantation
26.13°N
36 →
§ 03Getting Semaglutide in Delray Beach
32 providers · Delray Beach, FL

How to get Semaglutide in Delray Beach.

32 GLP-1 prescribers and 7 local resource types are on record for Delray Beach, plus 3 nearby towns in the directory.

Prescribers in Delray Beach
32 prescribers
32 GLP-1 prescribers in Delray Beach, most listed as Family Medicine (12), Internal Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (4). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Boca Raton (42 providers), Coral Springs (31 providers) and Wellington (28 providers).
Around the prescription in Delray Beach
7 listed nearby
26 dietitians, 7 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 4 places to move are on record near Delray Beach.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Delray Beach

Delray Beach, Florida has a population of 66,846 people. The adult obesity rate in Delray Beach is an age-adjusted estimate of 27.7%, 1.9 percentage points below the Florida state rate of 29.6%. Diagnosed diabetes reaches 10.4% of adults in Delray Beach. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.1% of adults in Delray Beach.

of Delray Beach adults have obesity
27.7%
diagnosed diabetes
10.4%
no regular physical activity
23.1%

Age-adjusted estimates for Delray Beach, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Semaglutide in Delray Beach
6 fitness clubs

The prescription is one part. Here is the rest, in Delray Beach.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Delray Beach, FL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

LivWel Strength & Conditioning
FITNESS
5.0 on Google · 353 reviews
2158 W Atlantic Ave
Website
The LIFT Lounge® ️ | Longevity Training Studio
FITNESS
5.0 on Google · 136 reviews
405 SE 6th Ave Ste 101
Website
Core Shake Studio
FITNESS
4.9 on Google · 41 reviews
401 W Atlantic Ave STE R10
Website
Body Geneius
FITNESS
5.0 on Google · 40 reviews
1325 N Federal Hwy Ste 111
Website
Planet Fitness
GYM
4.2 on Google · 887 reviews
14550 S Military Trl
Website
HEW Fitness
GYM
5.0 on Google · 217 reviews
5195 W Atlantic Ave B
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kimberly Altman, Dietitian
RD
Registered dietitian
27385 Saint Lucie Ln
Call 609-509-4969NPI 1225235708
Brooke Andrews, MS, RDN, CISSN
RD
Registered dietitian
4337 Sylvester Palm Dr
Call 727-688-9584NPI 1578969978
Samantha Barone, RD
RD
Registered dietitian
4600 Linton Blvd Ste 250
Call 561-500-4673NPI 1053834796
Sondra Braude, RD, LD/N
RD
Registered dietitian
120 Se 4Th Ave
Call 561-266-8866NPI 1568840072
Shaleen Burgess
RD
Registered dietitian
4800 Linton Blvd Ste F107
Call 561-455-1336NPI 1306250493
Leslie Burman, R.D., L.D
RD
Registered dietitian
22971 Via Desonrisa Del Norte
Call 561-789-7000NPI 1003069204
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Florida

NPI-verified Semaglutide (semaglutide) prescribers and clinics, never ranked by who pays us.

Weight loss doctors in Florida
Prescribers verified against the federal NPI registry.
Weight loss clinics in Florida
Clinics running GLP-1 programs, telehealth & in-person.
Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Semaglutide in Alabama→Semaglutide in Alaska→Semaglutide in Arizona→Semaglutide in Arkansas→Semaglutide in California→Semaglutide in Colorado→Semaglutide in Connecticut→Semaglutide in Delaware→Semaglutide in Florida→Semaglutide in Georgia→Semaglutide in Hawaii→Semaglutide in Idaho→Semaglutide in Illinois→Semaglutide in Indiana→Semaglutide in Iowa→Semaglutide in Kansas→Semaglutide in Kentucky→Semaglutide in Louisiana→Semaglutide in Maine→Semaglutide in Maryland→Semaglutide in Massachusetts→Semaglutide in Michigan→Semaglutide in Minnesota→Semaglutide in Mississippi→Semaglutide in Missouri→Semaglutide in Montana→Semaglutide in Nebraska→Semaglutide in Nevada→Semaglutide in New Hampshire→Semaglutide in New Jersey→Semaglutide in New Mexico→Semaglutide in New York→Semaglutide in North Carolina→Semaglutide in North Dakota→Semaglutide in Ohio→Semaglutide in Oklahoma→Semaglutide in Oregon→Semaglutide in Pennsylvania→Semaglutide in Rhode Island→Semaglutide in South Carolina→Semaglutide in South Dakota→Semaglutide in Tennessee→Semaglutide in Texas→Semaglutide in Utah→Semaglutide in Vermont→Semaglutide in Virginia→Semaglutide in Washington→Semaglutide in West Virginia→Semaglutide in Wisconsin→Semaglutide in Wyoming→
Related GLP-1 research
GLP-1s and hair loss
Why rapid loss can shed hair, and what helps it regrow.
how long GLP-1s take to work
When appetite changes show up, and when the weight curve usually follows.
oral and sublingual GLP-1 options
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Semaglutide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]